Canadian Biotech Advances High-Impact DDR Programs
Source: Streetwise Reports  (6/6/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy. More >

Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports  (6/6/25)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock. More >

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports  (6/6/25)
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

More >

Data Readout Positive from Trial of New Schizophrenia Drug
Source: Jason Kolbert  (6/4/25)
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report. More >

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada
Source: Streetwise Reports  (5/30/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market More >

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern
Source: Clive Maund  (5/27/25)
Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy. More >

Co. Poised to Begin Major New Bull Market
Source: Clive Maund  (5/23/25)
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy. More >

Treatment.com AI's Rocket Doctor Expands US Reach and Drives New Growth Through Virtual ER Innovation
Source: Streetwise Reports  (5/23/25)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) virtual care subsidiary, Rocket Doctor, has expanded its core virtual care services into New York and California. Separately, its virtual ER program, designed to reduce unnecessary emergency room visits, continues to demonstrate a strong impact. Over a 12-month period between 2023 and 2024, Rocket Doctor reported an 88% year-over-year increase in revenue." More >

Centrally Positioned AI Co. Platform Designed To Transform Healthcare
Source: Clive Maund  (5/21/25)
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA). More >

Co. Prepares to Roll Out Wound Irrigating Solution
Source: Richard Ryan  (5/21/25)
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report. More >

Interim Data From TID Trial Are Positive
Source: Streetwise Reports  (5/15/25)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. More >

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Source: Streetwise Reports  (5/13/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential. More >

Biopharma Receives PDUFA Date for Lead Program
Source: Jason Kolbert  (5/9/25)
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report. More >

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell  (5/1/25)
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report. More >

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado  (5/1/25)
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Source: Streetwise Reports  (4/29/25)
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock. More >

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports  (4/28/25)
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.

More >

Biotech Company Reports Promising Neurological Treatment in Clinical Study
Source: Streetwise Reports  (4/25/25)
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year. More >

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports  (4/24/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company. More >

Biotech Discovers Revolutionary Immunotherapy in Houston
Source: Jason Kolbert  (4/24/25)
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. More >

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe  (4/14/25)
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. More >

New Drug for Early AD Shown to be Efficacious, Safe
Source: Jason Kolbert  (4/9/25)
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. More >

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert  (4/9/25)
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. More >

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju  (4/9/25)
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. More >